With what evidence, what data is the impact of the protective program measured?
- Timestamped, non-manually entered measurement from the device; accredited device accuracy
- Person, device, and measurement continuity are traceable; non-measuring insured individuals are also visible
- Anonymous statistics for aggregate analysis
- Program and control group comparison is built into the pilot design from the start
- –27%: for every 10 mmHg reduction in systolic blood pressure, 613,815 fewer strokes
-
Ettehad et al., Lancet 2016
- –21.9%: medical expenditure among participants in a remote diabetes program, $88 per member per month
-
Whaley et al., J Med Econ 2019
- 1.2 mmHg: the largest pressure measurement deviation of the device (limit ±3)
-
TÜRKAK-accredited laboratory, 2025
Pilot target
The proportion of evaluable data in the pilot, measurement continuity, and comparison with the control group are reported; financial modeling is conducted using the institution's own methods.